TY  - JOUR
TI  - Anti-angiogenesis in cancer; met and unmet goals - an interview with Robert Kerbel
AU  - Bertolini, Francesco
T2  - The International Journal of Developmental Biology
AB  - Robert Kerbel is one of the most influential scientists in the field of cancer-related angiogenesis and anti-angiogenic therapies. Along with the late Judah Folkman, Dr. Kerbel has also pioneered the use of continuous low dose chemotherapy for cancer treatment, an approach which is now widely used for many types of cancer and is a promising backbone to be associated with novel targeted therapies. In this interview, Dr. Kerbel describes the steps that moved his career towards the angiogenesis field, the already achieved biological and clinical results and the unmet goals.
PY  - 2011
DO  - 10.1387/ijdb.103217fb
VL  - 55
IS  - 4-5
SP  - 395
EP  - 398
J2  - Int. J. Dev. Biol.
LA  - en
SN  - 0214-6282
SN  - 1696-3547
UR  - https://ijdb.ehu.eus/article/103217fb
Y2  - 2024/11/21/18:38:42
ER  -